Skip to main content
Top
Published in: Neurotherapeutics 1/2017

01-01-2017 | Review

Urate as a Marker of Risk and Progression of Neurodegenerative Disease

Authors: Sabrina Paganoni, Michael A. Schwarzschild

Published in: Neurotherapeutics | Issue 1/2017

Login to get access

Abstract

Urate is a naturally occurring antioxidant whose levels are associated with reduced risk of developing Parkinson’s disease (PD) and Alzheimer’s disease. Urate levels are also associated with favorable progression in PD, amyotrophic lateral sclerosis, Huntington’s disease, and multisystem atrophy. These epidemiological data are consistent with laboratory studies showing that urate exhibits neuroprotective effects by virtue of its antioxidant properties in several preclinical models. This body of evidence supports the hypothesis that urate may represent a shared pathophysiologic mechanism across neurodegenerative diseases. Most importantly, beyond its role as a molecular predictor of disease risk and progression, urate may constitute a novel therapeutic target. Indeed, clinical trials of urate elevation in PD and amyotrophic lateral sclerosis are testing the impact of raising peripheral urate levels on disease outcomes. These studies will contribute to unraveling the neuroprotective potential of urate in human pathology. In parallel, preclinical experiments are deepening our understanding of the molecular pathways that underpin urate’s activities. Altogether, these efforts will bring about new insights into the translational potential of urate, its determinants, and its targets and their relevance to neurodegeneration.
Appendix
Available only for authorised users
Literature
1.
go back to reference D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 2013;65:509–527.CrossRefPubMed D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 2013;65:509–527.CrossRefPubMed
2.
go back to reference Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008;4:600–609.CrossRefPubMed Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008;4:600–609.CrossRefPubMed
4.
go back to reference Yeum KJ, Russell RM, Krinsky NI, Aldini G. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys 2004;430:97–103.CrossRefPubMed Yeum KJ, Russell RM, Krinsky NI, Aldini G. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys 2004;430:97–103.CrossRefPubMed
5.
go back to reference Fabbrini E, Serafini M, Colic Baric I, Hazen SL, Klein S. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes 2014;63:976–981.CrossRefPubMedPubMedCentral Fabbrini E, Serafini M, Colic Baric I, Hazen SL, Klein S. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes 2014;63:976–981.CrossRefPubMedPubMedCentral
6.
go back to reference Johnson RJ, Titte S, Cade JR, Rideout BA, Oliver WJ. Uric acid, evolution and primitive cultures. Semin Nephrol 2005;25:3–8.CrossRefPubMed Johnson RJ, Titte S, Cade JR, Rideout BA, Oliver WJ. Uric acid, evolution and primitive cultures. Semin Nephrol 2005;25:3–8.CrossRefPubMed
7.
8.
go back to reference Torralba KD, De Jesus E, Rachabattula S. The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. Int J Rheum Dis 2012;15:499–506.CrossRefPubMed Torralba KD, De Jesus E, Rachabattula S. The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. Int J Rheum Dis 2012;15:499–506.CrossRefPubMed
9.
go back to reference Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008;40:437–442.CrossRefPubMed Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008;40:437–442.CrossRefPubMed
10.
go back to reference Schwarzschild MA, Ascherio A, Beal MF, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014;71:141–150.CrossRefPubMed Schwarzschild MA, Ascherio A, Beal MF, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014;71:141–150.CrossRefPubMed
11.
go back to reference Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:6858–6862.CrossRefPubMedPubMedCentral Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:6858–6862.CrossRefPubMedPubMedCentral
12.
go back to reference Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 1994;33:419–425.CrossRefPubMed Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 1994;33:419–425.CrossRefPubMed
13.
go back to reference Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 1996;144:480–484.CrossRefPubMed Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 1996;144:480–484.CrossRefPubMed
14.
go back to reference Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561–567. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561–567.
15.
go back to reference Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2009;169:1064–1069 Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2009;169:1064–1069
16.
go back to reference de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005;58:797–800. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005;58:797–800.
17.
go back to reference Uribe-San Martin R, Venegas Francke P, Lopez Illanes F, et al. Plasma urate in REM sleep behavior disorder. Mov Disord 2013;28:1150–1151. Uribe-San Martin R, Venegas Francke P, Lopez Illanes F, et al. Plasma urate in REM sleep behavior disorder. Mov Disord 2013;28:1150–1151.
18.
go back to reference Gao X, Chen H, Choi HK, Curhan G, SchwarzschildMA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 2008;167:831–838. Gao X, Chen H, Choi HK, Curhan G, SchwarzschildMA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 2008;167:831–838.
19.
go back to reference Facheris MF, Hicks AA, Minelli C, et al. Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease. J Mol Neurosci 2011;43:246–250. Facheris MF, Hicks AA, Minelli C, et al. Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease. J Mol Neurosci 2011;43:246–250.
20.
go back to reference Gonzalez-Aramburu I, Sanchez-Juan P, Jesus S, et al. Genetic variability related to serum uric acid concentration and risk of Parkinson's disease. Mov Disord 2013;28:1737–1740. Gonzalez-Aramburu I, Sanchez-Juan P, Jesus S, et al. Genetic variability related to serum uric acid concentration and risk of Parkinson's disease. Mov Disord 2013;28:1737–1740.
21.
go back to reference Lu N, DubreuilM, Zhang Y, et al. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Ann Rheum Dis 2016;75:547–551. Lu N, DubreuilM, Zhang Y, et al. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Ann Rheum Dis 2016;75:547–551.
22.
go back to reference Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008;65:716–723. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008;65:716–723.
23.
go back to reference Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460–1468. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460–1468.
24.
go back to reference Simon KC, Eberly S, Gao X, et al. Mendelian randomization of serum urate and parkinson disease progression. Ann Neurol 2014;76:862–868. Simon KC, Eberly S, Gao X, et al. Mendelian randomization of serum urate and parkinson disease progression. Ann Neurol 2014;76:862–868.
25.
go back to reference Paganoni S, Zhang M, Quiroz Zarate A, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 2012;259:1923–1928. Paganoni S, Zhang M, Quiroz Zarate A, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 2012;259:1923–1928.
26.
go back to reference Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a metaanalysis. J Neurol 2014;261:1133–1138. Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a metaanalysis. J Neurol 2014;261:1133–1138.
27.
go back to reference Atassi N, Berry J, Shui A, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719–1725. Atassi N, Berry J, Shui A, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719–1725.
28.
go back to reference Kuffner R, Zach N, Norel R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol 2015;33:51–57. Kuffner R, Zach N, Norel R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol 2015;33:51–57.
29.
go back to reference Zheng Z, Guo X, Wei Q, et al. Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population. Metab Brain Dis 2014;29:771–775. Zheng Z, Guo X, Wei Q, et al. Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population. Metab Brain Dis 2014;29:771–775.
30.
go back to reference Chio A, Calvo A, Bovio G, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol 2014;71:1134–1142. Chio A, Calvo A, Bovio G, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol 2014;71:1134–1142.
31.
go back to reference Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington's disease progression. Mov Disord 2010;25:224–228. Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington's disease progression. Mov Disord 2010;25:224–228.
32.
go back to reference Irizarry MC, Raman R, Schwarzschild MA, et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 2009;6:23–28. Irizarry MC, Raman R, Schwarzschild MA, et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 2009;6:23–28.
33.
go back to reference Lee JE, Song SK, SohnYH, Lee PH.Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord 2011;26:1533–1536. Lee JE, Song SK, SohnYH, Lee PH.Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord 2011;26:1533–1536.
34.
go back to reference Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLOS ONE 2012;7:e37331. Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLOS ONE 2012;7:e37331.
35.
go back to reference ChenX, Burdett TC, Desjardins CA, et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A 2013;110:300–305. ChenX, Burdett TC, Desjardins CA, et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A 2013;110:300–305.
36.
go back to reference Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. J Neurochem 2012;123:172–181. Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. J Neurochem 2012;123:172–181.
37.
go back to reference Du Y, Chen CP, Tseng CY, Eisenberg Y, Firestein BL. Astrogliamediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 2007;55:463–472. Du Y, Chen CP, Tseng CY, Eisenberg Y, Firestein BL. Astrogliamediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 2007;55:463–472.
38.
go back to reference Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998;53:613–625. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998;53:613–625.
39.
go back to reference Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci U S A 2005;102:3483–3488. Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci U S A 2005;102:3483–3488.
40.
go back to reference Romanos E, Planas AM, Amaro S, Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood FlowMetab 2007;27:14–20. Romanos E, Planas AM, Amaro S, Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood FlowMetab 2007;27:14–20.
41.
go back to reference Kean RB, Spitsin SV, Mikheeva T, Scott GS, Hooper DC. The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol 2000;165:6511–6518. Kean RB, Spitsin SV, Mikheeva T, Scott GS, Hooper DC. The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol 2000;165:6511–6518.
42.
go back to reference Chamorro A, Amaro S, CastellanosM, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol 2014;13:453–460. Chamorro A, Amaro S, CastellanosM, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol 2014;13:453–460.
43.
go back to reference Llull L, Laredo C, Renu A, et al. Uric acid therapy improves clinical outcome in women with acute ischemic stroke. Stroke 2015;46: 2162–2167. Llull L, Laredo C, Renu A, et al. Uric acid therapy improves clinical outcome in women with acute ischemic stroke. Stroke 2015;46: 2162–2167.
44.
go back to reference Annanmaki T, Muuronen A,Murros K. Low plasma uric acid level in Parkinson's disease. Mov Disord 2007;22:1133–1137. Annanmaki T, Muuronen A,Murros K. Low plasma uric acid level in Parkinson's disease. Mov Disord 2007;22:1133–1137.
45.
go back to reference BogdanovM,MatsonWR,Wang L, et al.Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008;131:389–396. BogdanovM,MatsonWR,Wang L, et al.Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008;131:389–396.
46.
go back to reference Lawton KA, Brown MV, Alexander D, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:362–370. Lawton KA, Brown MV, Alexander D, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:362–370.
47.
go back to reference Keizman D, Ish-ShalomM, Berliner S, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci 2009;285:95–99. Keizman D, Ish-ShalomM, Berliner S, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci 2009;285:95–99.
48.
go back to reference Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease: a prospective study. Neurology 2007;69:1696–1700. Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease: a prospective study. Neurology 2007;69:1696–1700.
49.
go back to reference Gong L, Zhang QL, Zhang N, et al. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/ GSK3beta signaling pathway. J Neurochem 2012;123:876–885. Gong L, Zhang QL, Zhang N, et al. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/ GSK3beta signaling pathway. J Neurochem 2012;123:876–885.
50.
go back to reference Jones DC, Gunasekar PG, Borowitz JL, Isom GE. Dopamineinduced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells. J Neurochem 2000;74:2296–2304. Jones DC, Gunasekar PG, Borowitz JL, Isom GE. Dopamineinduced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells. J Neurochem 2000;74:2296–2304.
51.
go back to reference Zhu TG, Wang XX, Luo WF, et al. Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci Lett 2012;506:175–179. Zhu TG, Wang XX, Luo WF, et al. Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci Lett 2012;506:175–179.
52.
go back to reference Duan W, Ladenheim B, Cutler RG, Kruman, II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002;80:101–110. Duan W, Ladenheim B, Cutler RG, Kruman, II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002;80:101–110.
53.
go back to reference Guerreiro S, Ponceau A, Toulorge D, et al. Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J Neurochem 2009;109:1118–1128. Guerreiro S, Ponceau A, Toulorge D, et al. Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J Neurochem 2009;109:1118–1128.
54.
go back to reference Bakshi R, Zhang H, Logan R, et al. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiol Dis 2015;82:574–579. Bakshi R, Zhang H, Logan R, et al. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiol Dis 2015;82:574–579.
55.
go back to reference Zhang N, Shu HY, Huang T, et al. Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLOS ONE 2014;9:e100286. Zhang N, Shu HY, Huang T, et al. Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLOS ONE 2014;9:e100286.
56.
go back to reference Onetti Y, Dantas AP, Perez B, et al. Middle cerebral artery remodeling following transient brain ischemia is linked to early postischemic hyperemia: a target of uric acid treatment. Am J Physiol Heart Circ Physiol 2015;308:H862–H874. Onetti Y, Dantas AP, Perez B, et al. Middle cerebral artery remodeling following transient brain ischemia is linked to early postischemic hyperemia: a target of uric acid treatment. Am J Physiol Heart Circ Physiol 2015;308:H862–H874.
57.
go back to reference Johnson RJ. Why focus on uric acid? Curr Med Res Opin 2015;31(Suppl. 2):3–7. Johnson RJ. Why focus on uric acid? Curr Med Res Opin 2015;31(Suppl. 2):3–7.
Metadata
Title
Urate as a Marker of Risk and Progression of Neurodegenerative Disease
Authors
Sabrina Paganoni
Michael A. Schwarzschild
Publication date
01-01-2017
Publisher
Springer US
Published in
Neurotherapeutics / Issue 1/2017
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-016-0497-4

Other articles of this Issue 1/2017

Neurotherapeutics 1/2017 Go to the issue